再生醫療：在骨頭及關節上的應用 是由出版商BCC Research在2009年10月所出版的。
這份英文市場調查報告書包含269 pages 價格從美金4850起跳。
本報告書內容包括：全球應用於骨頭、關節上的再生醫療市場綜合分析、2014年之前的市場成長預測、包括現有治療方法的主要再生醫療技術動向、法規限制問題、主要企業介紹等。內容綱要摘記如下：
第1章 介紹
第2章 摘要
第3章 概要及產業動向
- 再生醫療市場的範圍
- 再生醫療的應用方法
- 組織置換是每年有1,000億美元商機的事業
- 再生醫療的阻礙
- 現在的研發動向
- 2015年∼2030年的發展預測
- 再生醫療及醫療經濟學
- 人口動向
- 拓展海外市場的行動 其他
第4章 再生醫療的基本方針
- 再生醫療的基本方針
- 細胞及組織
- 組織工程
- 2008年∼2010年的工程及生物材料
- ES細胞
- 治療用克隆
- 成人幹細胞
- 幹細胞研究專利及對幹細胞市場中企業造成的影響
- 再生醫療在骨頭・關節疾病治療中的應用
- 新的材料
- 基因治療
- 生物反應器於再生醫療中的應用
- 基因體學的影響
第5章 產品及技術：再生醫療分類
- 基因・蛋白質
- 抗體
- 成長因素
- BMPS功能
- 細胞及組織
- 組織工程
- 人工皮膚 其他
第6章 幹細胞治療及再生醫療
- 做為置換細胞的幹細胞
- 技術課題
- 資金投入
- 針對幹細胞研究的州政府行動
- 體外工程再造
- 臍帶血幹細胞 其他
第7章 應用於骨頭疾病治療的再生產品
第8章 骨・關節的再生技術應用
- 骨頭組織修復材料
- 骨骼再生能力
- 人工骨商業的規模
- 自體組織 其他
第9章 電力骨骼成長刺激材料市場
第10章 整型外科：FDA的許可及新產品開發
第11章 組織工程產品市場
第12章 牙科的再生概念及產品
第13章 皮膚技術
第14章 再生醫療在神經科中的應用
第15章 在心臟病上的應用
第16章 再生醫療及糖尿病
第17章 再生醫療相關FDA許可的臨床檢查
第18章 海外行動
第19章 專利分析
第20章 企業介紹
第21章 再生醫療商業的名詞解釋
Abstract
THIS REPORT:
- Provides a comprehensive overview of the global market for regenerative
medicines for bone and joint applications
- Offers the background for demographics underlying the market for bone and
joint products
- Contains global market forecasts for regenerative medicines for bone and
joint applications, with trends and forecasts for growth through 2014
- Describes the leading bone and joint diseases and disorders using
regenerative technologies, including incidence and current methods of treatment
- Discusses regulatory issues affecting regenerative medicine products
- Profiles leading and emerging companies.
INTRODUCTION
Regenerative medicine is a relatively large and rapidly evolving segment of
the healthcare business. The regenerative medicine industry has been in
existence for nearly 25 years. Actual product sales, along with research and
development (R&D) expenditures, are projected to amount to approximately $2
billion in economic activity in 2009. Bone and joint applications account for
a little more than half of those revenues, or $1.2 billion. The rapid
evolution of this business is evidenced by the industry consolidation that has
occurred since the first edition of this BCC Research report was published in
2003. In addition, intensive R&D efforts at universities and the National
Institutes of Health that focus on cutting-edge technology underscore the
importance of this industry.
The key objective of regenerative medicine is the utilization of living cells
to repair or replace body tissue damaged by injury, disease, or the aging
process. The most successful products have drawn upon multidisciplinary fields
such as biology, medicine, engineering, and particularly biomedical
engineering. The principal focus in this report is on bone and joint
applications; however, other regenerative applications such as dental,
neurologic, organ regeneration, cardiovascular, urologic, diabetes, and wound
care are important. Stem-cell research is an important component of the sector
as well. For example, the successful differentiation of embryonic stem cells
into specific cell types is widely sought as a means to treat traumatic
spinal-cord injury, as well as diseases such as diabetes, Duchenne muscular
dystrophy, heart disease, and vision and hearing loss.
OBJECTIVES AND GOALS OF STUDY
This report focuses on the bone- and joint-related applications and markets
for the various categories of regenerative medicine products currently
available and projected to be introduced during the 5-year forecast period
from 2009 to 2014. Market drivers discussed include an increase in diseases
and disorders that will benefit from these products, primarily arthritis,
osteoporosis, and various types of bone and joint trauma (e.g., hip fractures,
knee injuries); increasing use of non-autograft products by physicians; and
innovative devices that incorporate bone- and cartilage-growth-stimulating
agents in a regenerative appliance. Products discussed include bone and
cartilage grafting and regenerative products derived from autologous,
allogeneic, and synthetic sources, as well as electrical stimulators for bone
growth and regenerative cartilage products.
Profiles are provided of leading and emerging companies in the bone and joint
regenerative medicine markets, along with analyses of the current and future
positioning of their products and businesses in this active and rapidly
changing market.
INTENDED AUDIENCE
The aim of this report is to provide an overview of regenerative medicine
products, both available and emerging, for the treatment of diseases and
disorders of the bones and joints. The information and analysis presented are
important assets in decision making for managers involved in business
development, marketing, market research, product development, mergers and
acquisitions, licensing, business management, investment banking, and deal
creation, as well as to consultants to the pharmaceutical and biotechnology
industries. The study provides a comprehensive analysis of the current markets
for regenerative medicine products for bones and joints, relevant
applications, and the potential of products in development.
SCOPE OF REPORT
The U.S. has been the main regenerative medicine market both in terms of R&D
innovation and product sales; hence, the scope of the study is mainly U.S.,
although worldwide developments are discussed where relevant. The Overview
section provides a background of the demographics underlying the market for
bone and joint products, a definition of regenerative medicine and the
technologies involved, and a discussion of regenerative products in
development for applications other than bones and joints. Various applications
sections describe the leading bone and joint diseases and disorders applicable
to regenerative technologies, including incidence and current methods of
treatment.
The section on Products provides extensive descriptions and analyses (e.g.,
comparative analysis) of regenerative products used to treat bone and joint
disorders, as well as a discussion of products in development.
The section on FDA clinical trials and newly approved products provides a
discussion of regulatory issues affecting regenerative medicine products.
An extensive Company Profiles section provides a concise exploration of
leading and emerging companies in the area of regenerative products for bones
and joints, including product introductions, patents, and overall business
strategies.
METHODOLOGY
Both primary and secondary research methodologies were used to prepare this
market research report. The base year for this study is 2009. Sales data are
estimated in nominal dollars (unadjusted for inflation). Information to
prepare this study was derived from market intelligence provided by chief
executive officers, marketing strategists, research executives, and others at
leading companies involved in the regenerative medicine market. Data was
accessed from government agencies and regulatory bodies that monitor and/or
regulate medical devices. Searches of secondary material such as company
annual reports and 10Ks, journal articles, prospectus assessments, government
resources, and data from healthcare institutions were conducted.
INFORMATION SOURCES
The information and analyses presented in this report are based on an
extensive survey of the biotechnology and pharmaceutical industries, as well
as a detailed examination of published literature and reports obtained from
regulatory authorities, medical research institutions, pharmaceutical trade
associations, and national and world health organizations.
Table of Contents
Chapter- 1: INTRODUCTION -- Complimentary 4
- OBJECTIVES AND GOALS OF STUDY 1
- INTENDED AUDIENCE 2
- SCOPE OF REPORT 2
- METHODOLOGY 3
- INFORMATION SOURCES 3
- ANALYST CREDENTIALS 3
- RELATED BCC REPORTS 3
- BCC ONLINE SERVICES 4
- DISCLAIMER 4
Chapter-2: SUMMARY 2
- SUMMARY (CONTINUED) 5
- SUMMARY TABLE U.S. MARKET FOR REGENERATIVE MEDICINE PRODUCTS USED IN BONE
AND JOINT APPLICATIONS, THROUGH 2014 ($ MILLIONS) 6
- SUMMARY FIGURE U.S. MARKET FOR REGENERATIVE MEDICINE PRODUCTS USED IN BONE
AND JOINT APPLICATIONS, 2007-2014 ($ MILLIONS) 6
Chapter-3: OVERVIEW AND OVERALL STATUS OF THE INDUSTRY 11
- TOTAL SCOPE OF REGENERATIVE MEDICINE MARKET 7
- TABLE 1 FUNCTIONAL ACTIVITIES WITH REGENERATIVE MEDICINE SECTOR 8
- HOW REGENERATIVE MEDICINE WORKS 8
- TISSUES AND ORGANS ON DEMAND 9
- ORGAN REPLACEMENT IS A $100 BILLION PER YEAR BUSINESS 10
- EXAMPLES OF IMPACT ON EXISTING CONDITIONS AND DISEASES 10
- BARRIERS TO REGENERATIVE MEDICINE 11
- CURRENT R&D PRIORITIES 12
- TABLE 2 PRINCIPAL REGENERATIVE MEDICINE BUSINESS R&D FOCUSES 13
- TABLE 3 20-YEAR PLANNING HORIZON FOR REGENERATIVE MEDICINE BUSINESS:
LIKELY DEVELOPMENTS, 2015-2030 14
- TOTAL OUTPUT OF THE SECTOR 15
- REGENERATIVE MEDICINE AND HEALTHCARE ECONOMICS 15
- POPULATION TRENDS 16
- MARKET TIMING 16
- OVERSEAS INITIATIVES 17
Chapter-4: PRINCIPLE APPROACHES TO REGENERATIVE MEDICINE 13
- GENE- AND PROTEIN-BASED APPROACHES 31
- ANTIBODIES 31
- The Importance of Antibody Drugs 32
- Advantages of Monoclonal Antibody Drugs 33
- Antibodies and Osteoarthritis 34
- GROWTH FACTORS 35
- GROWTH FACTORS (CONTINUED) 36
- HOW BMPS FUNCTION 37
- TABLE 6 BONE MORPHOGENETIC PROTEINS 38
- Clinical Uses 38
- Companies 39
- CELLS AND TISSUES 40
- TISSUE ENGINEERING 40
- ARTIFICIAL SKIN 41
- CARTILAGE 42
- OTHER APPROACHES TO CARTILAGE 43
- BIOSYNTHETIC COMPOSITES FOR CARTILAGE REPAIR 44
- THE MARKET FOR TISSUE-ENGINEERED CARTILAGE PRODUCTS 44
- TABLE 7 U.S. MARKET FOR TISSUE-ENGINEERED CARTILAGE PRODUCTS, THROUGH 2014
($ MILLIONS) 45
- OTHER PRODUCTS 45
- CREATION OF ENTIRE ORGANS 45
- CREATION OF ENTIRE ORGANS (CONTINUED) 46
- EMBRYONIC STEM CELLS 47
- NOVEL MATERIALS AND BIOMATERIALS 48
Chapter-5: PRODUCTS AND TECHNOLOGIES: CATEGORIES OF REGENERATIVE MEDICINE 18
Chapter-6: STEM CELL THERAPIES AND REGENERATIVE MEDICINE 18
- STEM CELLS AS POTENTIAL REPLACEMENT CELLS 49
- TECHNICAL IMPEDIMENTS 50
- OVERVIEW OF FUNDING 51
- TABLE 8 FEDERAL FUNDING FOR STEM CELL RESEARCH, THROUGH 2008 ($ MILLIONS)
52
- STATE-LEVEL INITIATIVES FOR STEM CELL RESEARCH 52
- TABLE 9 STATE LEVEL PROGRAMS FOCUSED ON STEM CELL RESEARCH 53
- POTENTIAL APPLICATIONS: CURRENT STATUS 53
- IN VIVO REPROGRAMMING 54
- UMBILICAL CORD BLOOD STEM CELLS 55
- Recent Research Developments 55
- INDUCED PLURIPOTENT STEM CELLS 56
- Recent Research Developments 56
- Adult Multipotent Stem Cells 57
- Embryonic Stem Cells 57
- Embryonic Stem Cells (Continued) 58
- GERON AND THE FIRST HUMAN TRIALS 59
- GERON AND THE FIRST HUMAN TRIALS (CONTINUED) 60
- OTHER STEM CELL RESEARCH 61
- STATUS OF OTHER CLINICAL TRIALS 62
- STEM CELL THERAPY FOR ALS 63
- STEM CELL THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY 64
- STEM CELL THERAPY AND BONE MARROW TRANSPLANTS 65
- Stem Cell Therapy and ... (Continued) 66
Chapter-7: REGENERATIVE PRODUCTS TO TREAT BONE DISEASES 33
- MATERIALS FOR BONE TISSUE REPAIR 100
- INHERENT REGENERATION OF BONE 100
- OVERALL SIZE OF BONE GRAFT BUSINESS 101
- BONE GRAFT SUBSTITUTES 102
- ALLOGRAFT TISSUE 103
- OTHER OSTEOCONDUCTIVE BONE GRAFT SUBSTITUTES 104
- HYDROGELS AND REGENERATION 105
- COMPOSITION AND METHOD FOR SELF-ASSEMBLY AND MINERALIZATION OF PEPTIDE
AMPHIPHILES 106
- CHONDROITINASE ABC I POLYNUCLEOTIDES 107
- Abstract 107
- TRANSDISCAL ADMINISTRATION OF CYCLINE COMPOUNDS 107
- Abstract 107
- COMPOSITION AND METHOD FOR PREPARING BIOCOMPATIBLE SURFACES 108
- Abstract 108
- SPINAL MOBILITY PRESERVATION APPARATUS HAVING AN EXPANDABLE MEMBRANE 108
- Abstract 108
- MAJOR DISEASES AND CONDITIONS AFFECTING BONES 109
- OSTEOPOROSIS 110
- Currently Available Products to Treat Osteoporosis 111
- Bisphosphonates 111
- Fosamax 112
- Boniva 113
- TABLE 19 DRUGS USED TO TREAT OSTEOPOROSIS 113
- Hormones 114
- Evista 114
- Forteo 114
- Forteo (Continued) 115
- Forteo (Continued) 116
- Miacalcin 117
- STEROIDS AND OSTEOPOROSIS 117
- Glucocorticoids 118
- THE MARKET FOR PRODUCTS TO TREAT OSTEOPOROSIS. 118
- TABLE 20 WORLDWIDE MARKET FOR DRUGS TO TREAT OSTEOPOROSIS, THROUGH 2014 ($
MILLIONS) 119
- FIGURE 4 WORLDWIDE MARKET FOR DRUGS TO TREAT OSTEOPOROSIS, 2007-2014 ($
MILLIONS) 119
- PAGET' S DISEASE 119
- DRUGS CURRENTLY AVAILABLE TO TREAT PAGET' S DISEASE 120
- Actonel 120
- Aredia 120
- Skelid 121
- Zometa 121
- THE MARKET FOR PRODUCTS TO TREAT PAGET' S DISEASE 121
- TABLE 21 WORLDWIDE MARKET FOR DRUGS TO TREAT PAGET' S DISEASE, THROUGH 2014
($ MILLIONS) 121
- FIGURE 5 WORLDWIDE MARKET FOR DRUGS TO TREAT PAGET' S DISEASE, 2007-2014 ($
MILLIONS) 122
- INJURIES AND DEGENERATIVE CONDITIONS 122
- HIP FRACTURES 123
- TABLE 22 WORLDWIDE HIP FRACTURE VOLUMES, THROUGH 2014 124
- TABLE 23 U.S. HIP FRACTURE VOLUMES, THROUGH 2014 124
- TRADITIONAL TREATMENTS FOR BONE AND JOINT DISORDERS 124
- TABLE 24 U.S. MARKET SHARES FOR MUSCULOSKELETAL PRODUCTS, 2008 (%) 125
- TABLE 25 U.S. RECONSTRUCTIVE DEVICE MARKET, 2008 (%) 125
- MARKET LEADERS 125
- JOINT-REPLACEMENT SURGERY 126
- TABLE 26 HIP REPLACEMENT PROCEDURE VOLUMES, U.S., THROUGH 2014 126
- TABLE 27 HISTORICAL RATES OF HIP REPLACEMEN IN SIX MAJOR STATES, 2001 126
- TABLE 28 WORLDWIDE HIP REPLACEMENT MARKET, THROUGH 2014 ($ MILLIONS) 127
- FIGURE 6 WORLDWIDE HIP REPLACEMENT MARKET, 2007-2014 ($ MILLIONS) 127
- TABLE 29 U.S. HIP REPLACEMENT MARKET, THROUGH 2014 ($ MILLIONS) 127
- FIGURE 7 U.S. HIP REPLACEMENT MARKET, 2007-2014 ($ MILLIONS) 128
- KNEE REPLACEMENTS 128
- TABLE 30 WORLDWIDE KNEE-REPLACEMENT PROCEDURE VOLUMES, THROUGH 2014 129
- TABLE 31 U.S. KNEE REPLACEMENT PROCEDURE VOLUMES, THROUGH 2014 129
- TABLE 32 WORLDWIDE KNEE REPLACEMENT MARKET, THROUGH 2014 ($ MILLIONS) 129
- FIGURE 8 WORLDWIDE KNEE REPLACEMENT MARKET, 2007-2014 ($ MILLIONS) 130
- TABLE 33 U.S. KNEE REPLACEMENT MARKET, THROUGH 2014 ($ MILLIONS) 130
- FIGURE 9 U.S. KNEE REPLACEMENT MARKET, 2007-2014 ($ MILLIONS) 131
- TABLE 34 U.S. MARKET FOR UNICONDYLAR KNEE REPLACEMENT, THROUGH 2014 ($
MILLIONS) 131
- FIGURE 10 U.S. MARKET FOR UNICONDYLAR KNEE REPLACEMENT, 2007-2014 ($
MILLIONS) 132
- NATURAL THERAPEUTIC TREATMENTS FOR ARTHRITIS 132
- IMAGING AND REGENERATION 133
- IMAGING AND REGENERATION (CONTINUED) 134
Chapter-8: REGENERATIVE APPLICATIONS FOR BONES AND JOINTS 35
Chapter-9: ELECTRICAL BONE GROWTH STIMULATOR MARKET 8
- OVERVIEW 135
- SCIENTIFIC BASIS 136
- ULTRASONIC OSTEOGENESIS STIMULATORS FOR BONE HEALING 137
- MARKETERS OF INVASIVE AND NONINVASIVE ELECTRICAL BONE GROWTH STIMULATORS
138
- BIOMET 138
- ORTHOFIX 139
- DJO, INC. 140
- SMITH & NEPHEW 141
- MARKET SIZE 141
- TABLE 35 WORLDWIDE MARKET FOR NONINVASIVE BONE GROWTH STIMULATORS, THROUGH
2014 ($ MILLIONS) 141
- TABLE 36 U.S. MARKET FOR NONINVASIVE BONE GROWTH STIMULATORS, THROUGH 2007
($ MILLIONS) 142
Chapter-10: ORTHOPEDICS - FDA CLEARANCES AND NEW PRODUCT DEVELOPMENT 16
- SUPPLIERS OF REGENERATIVE BONE AND JOINT PRODUCTS 143
- TABLE 37 RECENTLY APPROVED ORTHOPEDIC BONE AND JOINT DEVICES BY PRODUCT,
COMPANY, AND APPROVAL DATE, 2008 - 2009 144
- TABLE 37 (CONTINUED) 145
- TABLE 37 (CONTINUED) 146
- TABLE 37 (CONTINUED) 147
- TABLE 37 (CONTINUED) 148
- TABLE 37 (CONTINUED) 149
- TABLE 37 (CONTINUED) 150
- TABLE 37 (CONTINUED) 151
- TABLE 37 (CONTINUED) 152
- TABLE 37 (CONTINUED) 153
- TABLE 37 (CONTINUED) 154
- TABLE 37 (CONTINUED) 155
- TABLE 37 (CONTINUED) 156
- TABLE 37 (CONTINUED) 157
- TABLE 37 (CONTINUED) 158
Chapter-11: MARKET FOR TISSUE ENGINEERING PRODUCTS 4
- TISSUE ENGINEERING AND CELL THERAPY 159
- RESEARCH INITIATIVES 160
- RESEARCH INITIATIVES (CONTINUED) 161
- RESEARCH INITIATIVES (CONTINUED) 162
Chapter-12: REGENERATIVE CONCEPTS AND PRODUCTS IN DENTISTRY 3
- OVERVIEW 163
- INDICATIONS AND HISTORY 163
- CHARACTERTISTICS AND MATERIALS 164
- BARRIER MEMBRANES 164
- NON-RESORBABLE 164
- RESORBABLE 164
- COLLAGEN RESORBABLE MEMBRANES 165
- SYNTHETIC RESORBABLE MEMBRANES 165
Chapter-13: SKIN TECHNOLOGIES 3
- SKIN TECHNOLOGIES (CONTINUED) 166
- SKIN-LIKE TISSUE DEVELOPED FROM HUMAN EMBRYONIC STEM CELLS 167
- TABLE 38 SALES OF ENGINEERED SKIN GRAFTS AND REPLACEMENTS, THROUGH 2014 ($
MILLIONS) 168
Chapter-14: NEUROLOGICAL APPLICATIONS IN REGENERATIVE MEDICINE 4
- OVERVIEW 169
- NEURODEGENERATIVE DISEASES 169
- CURRENT CONVENTIONAL THERAPIES FOR THE TREATMENT OF NEURODEGENERATIVE
DISEASE SYMPTOMS 169
- SPINAL CORD INJURY, NEURODEGENERATIVE DISEASES, AND REGENERATIVE POTENTIAL
170
- SPINAL CORD INJURY, ... (CONTINUED) 171
- UNIVERSITY OF SOUTHERN CALIFORNIA (USC) 172
Chapter-15: REGENERATIVE MEDICINE AND APPLICATIONS IN CARDIAC CARE 6
- OVERVIEW 173
- STEM CELLS FOR THE FUTURE TREATMENT OF HEART DISEASE 173
- PARTICULAR R&D PRIORITIES 174
- PARTICULAR R&D PRIORITIES (CONTINUED) 175
- STEM CELLS AND BIOLOGICAL PACEMAKERS 176
- HEART PROGENITOR CELLS DEVELOPED FROM EMBRYONIC STEM CELLS 176
- OTHER CURRENT REGENERATIVE MEDICINE AS IT RELATES TO THE HEART 177
- OTHER CURRENT REGENERATIVE ...(CONTINUED) 178
Chapter-16: REGENERATIVE MEDICINE AND DIABETES 2
- BACKGROUND 179
- POSSIBLE APPLICATIONS FOR REGENERATIVE MEDICINE 179
- POSSIBLE APPLICATIONS FOR ... (CONTINUED) 180
Chapter-17: FDA APPROVED CLINICAL TRIALS INVOLVING REGENERATIVE MEDICINE 29
- CURRENT STATUS OF THE REGENERATIVE MEDICINE BUSINESS 181
- REGULATORY ENVIRONMENT 181
- REGULATORY ENVIRONMENT (CONTINUED) 182
- STATUS OF RESEARCH AND CLINICAL TRIALS 183
- ANALYSIS OF CLINICAL TRIALS 184
- TABLE 39 REGENERATIVE MEDICINE CLINICAL TRIALS BY MAJOR CATEGORY 185
- TABLE 40 CURRENT CLINICAL TRIALS IN THE FIELD OF REGENERATIVE MEDICINE
STATUS, CONDITIONS, INTERVENTION, AND SPONSOR 185
- TABLE 40 (CONTINUED) 186
- TABLE 40 (CONTINUED) 187
- TABLE 40 (CONTINUED) 188
- TABLE 40 (CONTINUED) 189
- TABLE 40 (CONTINUED) 190
- TABLE 40 (CONTINUED) 191
- TABLE 40 (CONTINUED) 192
- TABLE 40 (CONTINUED) 193
- TABLE 40 (CONTINUED) 194
- TABLE 40 (CONTINUED) 195
- TABLE 40 (CONTINUED) 196
- TABLE 40 (CONTINUED) 197
- TABLE 40 (CONTINUED) 198
- TABLE 40 (CONTINUED) 199
- TABLE 40 (CONTINUED) 200
- TABLE 40 (CONTINUED) 201
- TABLE 40 (CONTINUED) 202
- TABLE 40 (CONTINUED) 203
- TABLE 40 (CONTINUED) 204
- TABLE 40 (CONTINUED) 205
- TABLE 40 (CONTINUED) 206
- TABLE 40 (CONTINUED) 207
- TABLE 40 (CONTINUED) 208
- TABLE 40 (CONTINUED) 209
Chapter-18: OVERSEAS ACTIVITIES 3
- DOMESTIC VERSUS OVERSEAS REGENERATIVE MEDICINE COMPANIES 210
- JAPAN 210
- EUROPE 211
- AUSTRALIA AND CHINA 212
Chapter-19: PATENT ANALYSIS 5
- ANALYSIS 213
- TISSUE ENGINEERING PATENTS 213
- TABLE 41 MOST FREQUENTLY CITED PATENT ASSIGNEES IN TISSUE ENGINEERING
FIELD 214
- GEOGRAPHIC DISTRIBUTION 214
- TABLE 42 WORLD DISTRIBUTION OF REGENERATIVE MEDICINE PATENTS ISSUED, 1985
- 2009 (%) 215
- RECENT PATENTS 215
- DIRECT DIFFERENTIATION METHOD FOR MAKING CARDIOMYOCYTES FROM HUMAN
EMBRYONIC STEM CELLS 215
- Abstract 215
- METHOD FOR PREPARING NOVEL TRANSCRIPTION FACTORS AND USE 216
- Abstract 216
- ENDODERM CELLS FROM HUMAN EMBRYONIC STEM CELLS 216
- Abstract 216
- GENES WITH ES CELL-SPECIFIC EXPRESSION 217
- Abstract 217
- MARKER SYSTEM FOR PREPARING AND CHARACTERIZING HIGH-QUALITY HUMAN
EMBRYONIC STEM CELLS 217
- Abstract 217
Chapter-20: COMPANY PROFILES 45
- TABLE 43 PUBLICALLY TRADED COMPANIES IN THE REGENERATIVE MEDICINE
INDUSTRY, AS OF JULY 1, 2009 218
- AASTROM BIOSCIENCES, INC. 219
- ADVANCED BIOHEALING, INC. 219
- ADVANCED CELL TECHNOLOGY, INC. 220
- AESCULAP, INC. 221
- ALDAGEN, INC. 221
- ALPHATEC SPINE, INC. 222
- ANGIOTECH PHARMACEUTICALS, INC. 222
- ARTERIOCYTE MEDICAL SYSTEMS, INC. 223
- ARTHREX, INC. 223
- ARTHROCARE CORPORATION 223
- BIOMET, INC. 224
- BIOMIMETIC THERAPEUTICS, INC. 224
- BIOTISSUE TECHNOLOGIES GMBH 224
- CAPSTONE THERAPEUTICS 225
- CENTERPULSE ORTHOPAEDICS, INC. 226
- CERAPEDICS, INC. 226
- CITAGENIX, INC. 226
- CONMED CORPORATION 227
- CROSSCART INC. 228
- CRYOLIFE, INC. 229
- CURIS 230
- CYTORI THERAPEUTICS, INC. 231
- DEPUY ORTHOPAEDICS, INC. (UNIT OF THE DEPUY COMPANIES) 231
- DJO SURGICAL 232
- ESBATECH AG 232
- ETEX CORPORATION 233
- EXACTECH, INC. 234
- FATE THERAPEUTICS, INC. 234
- GARNET BIOTHERAPEUTICS 234
- GENZYME BIOSURGERY 235
- GERON CORPORATION 236
- INTEGRA LIFESCIENCES HOLDING CORP. 236
- ISOTIS ORTHOBIOLOGICS, INC. (INTEGRA ORTHOBIOLOGICS) 237
- INTERNATIONAL STEM CELL 237
- INTERPORE CROSS INTERNATIONAL 238
- ISTO TECHNOLOGIES, INC. 239
- KENSEY NASH CORPORATION 240
- LIFECELL (A SUBSIDIARY OF KINETIC CONCEPTS, INC.) 241
- MCEWEN CENTRE FOR REGENERATIVE MEDICINE 241
- MCGOWAN INSTITUTE FOR REGENERATIVE MEDICINE 242
- MEDTRONIC, INC. 242
- MESOBLAST, LIMITED 243
- NATIONAL CENTER FOR REGENERATIVE MEDICINE 243
- NATIONAL TISSUE ENGINEERING CENTER (NTEC) 244
- NEURALSTEM 245
- NOVABONE PRODUCTS, LLC 246
- NOVARTIS CORPORATION 246
- NOVOCELL, INC. 246
- OPEXA THERAPEUTICS 246
- ORGANOGENESIS INC. 247
- ORTHOFIX INTERNATIONAL N.V. 248
- ORTHOPEUTICS, L.P. 248
- ORTHOVITA, INC. 249
- OSIRIS THERAPEUTICS, INC. 249
- OSTEOTECH, INC. 250
- PFIZER, INC. 250
- PLURISTEM THERAPEUTICS 250
- REGEN BIOLOGICS, INC. 251
- RENEURON 252
- RTI BIOLOGICS, INC. 252
- SCIL TECHNOLOGY GMBH 252
- SMITH AND NEPHEW 253
- STEMCELLS, INC. 253
- STEMCOR SYSTEMS, INC. 254
- STRAUMANN USA LLC 254
- STRYKER CORP. 255
- SYNTHES, INC. 255
- TENGION 256
- TEPHA 257
- THERMOGENESIS CORP. 257
- TIGENIX N.V. 258
- UCB S.A. (HEADQUARTERS) 259
- WAKE FOREST INSTITUTE FOR REGENERATIVE MEDICINE 259
- WRIGHT MEDICAL GROUP, INC. 260
- ZIMMER HOLDINGS, INC. 261
- OTHER ORGANIZATIONS INVOLVED IN REGENRERATIVE MEDICINE R&D 261
- ACADEMIC INSTITUTIONS 261
- U.S. GOVERNMENT 262
- OTHER SOCIETIES AND ORGANIZATIONS 262
Chapter-21: GLOSSARY OF KEY TERMS IN REGENERATIVE MEDICINE BUSINESS 7
- GLOSSARY OF KEY TERMS 263
- GLOSSARY OF KEY TERMS (CONTINUED) 264
- GLOSSARY OF KEY TERMS (CONTINUED) 265
- GLOSSARY OF KEY TERMS (CONTINUED) 266
- GLOSSARY OF KEY TERMS (CONTINUED) 267
- GLOSSARY OF KEY TERMS (CONTINUED) 268
- GLOSSARY OF KEY TERMS (CONTINUED) 269
|
